Citations

Showing 10 of 108162 citations.

Tradition Versus Value: Is There Utility in Protocolized Postoperative Laboratory Testing After Elective Colorectal Surgery?
McKenna, Nicholas P. , Habermann, Elizabeth B. , Glasgow, Amy E. , Glasgow, Amy E. , Habermann, Elizabeth , McKenna, Nicholas P , Glasgow, Amy E , Cima, Robert R.

Mayo Clinic

Annals of Surgery | December 5, 2019 | Volume: 274 | Issue: 6 | Pages: e548-e553

10.1097/sla.0000000000003731 | PMID 31804397 Get It

Objective: Determine if routine ordering of postoperative day 1 (POD 1) serum laboratory tests after elective colorectal surgery are clinically warranted and valuable given the associated costs of these lab tests. Summary of Background Data: Routine postoperative serum laboratory tests are a part of many colorectal surgery order sets. Whether these protocolized lab tests represent cost-effective care is unknown. Methods: Patients undergoing elective colorectal surgery between January 1, 2015 and December 31, 2017 at our institution were identified. The protocolized POD 1 lab tests obtained as part of the postoperative order set were reviewed to determine the rate of abnormal values and any intervention in response. Costs associated with protocolized laboratory testing were calculated using dollar amounts representing 2017 outpatient Medicare reimbursement. Results: A total of 2252 patients were identified with 8205 total lab test values. Of these, only 4% were abnormal (3% of hemoglobin values, 6% of creatinine values, 3% of potassium of values, and 3% of glucose values), and only 1% were actively intervened upon. The total aggregate cost of the protocolized POD 1 laboratory tests in these years was $64,000 based on Medicare outpatient reimbursement dollars. Conclusions: Routine POD 1 lab tests after elective colorectal surgery are rarely abnormal, and they even less frequently require active intervention beyond rechecking. This results in increased resource utilization and cost of care without appreciable impact on clinical care, and is not cost-effective. Protocolized POD 1 laboratory testing should be replaced with clinically-based criteria to trigger serum laboratory investigations.
Is There a Role for Liver Transplantation in the Treatment of Patients With Metastatic Colorectal Cancer?
Rosen, Charles B. , Nagorney, David M. , Alberts, Steven R.

Mayo Clinic

Annals of Surgery | December 5, 2019 | Volume: 271 | Issue: 2 | Pages: 219-220

10.1097/sla.0000000000003713 | PMID 31804393 Get It

Retrospective Analysis of Antimicrobial Susceptibility Profiles of Nocardia Species from a Tertiary Hospital and Reference Laboratory, 2011 to 2017
Hamdi, Ahmed , Deml, Sharon M., Saleh, Omar Abu , Wengenack, Nancy L. , Hamdi, Ahmed M , Fida, Madiha , Abu Saleh, Omar M

Mayo Clinic

Antimicrobial Agents and Chemotherapy | December 5, 2019 | Volume: 64 | Issue: 3 | Pages: No page available

10.1128/aac.01868-19 | PMID 31818815 Get It

Nocardia species are found worldwide and are opportunistic pathogens of both immunocompromised and immunocompetent hosts. Recent updates to the taxonomy of this genus have indicated that there are more than 90 recognized species of Nocardia with 54 species reported to be clinically relevant.
Technical Aspects of Robot-Assisted Laparoscopic Lymphocele Excision with Intraperitonealization
Niu, Sida, Pate, Scott C., Duchêne, David Alejandro

Mayo Clinic

Videourology™ | December 5, 2019 | Volume: 34 | Issue: 1 | Pages: No page available

10.1089/vid.2019.0059 Get It

SAGE-Journals-Accessible-Video-Player 10.1089/vid.2019.0059.M1 sj-vid-1-vid-10.1089_vid.2019.0059
Lupus-associated endogenous retroviral LTR polymorphism and epigenetic imprinting promote HRES-1/RAB4 expression and mTOR activation
Godavarthy, Aparna, Jimah, John R. , Beckford, Miguel, Caza, Tiffany , Fernández, David , Huang, Nick , Duarte, Manuel, Fadel, Hind J., Poeschla, Eric M. , Bánki, Katalin, Perl, András , Kelly, Ryan, Fernández, David , Lewis, Joshua Richard

Mayo Clinic

JCI Insight | December 5, 2019 | Volume: 5 | Issue: 1 | Pages: No page available

10.1172/jci.insight.134010 | PMID 31805010 Get It

Overexpression and long terminal repeat (LTR) polymorphism of the HRES‑1/Rab4 human endogenous retrovirus locus have been associated with T cell activation and disease manifestations in systemic lupus erythematosus (SLE). Although genomic DNA methylation is diminished overall in SLE, its role in HRES-1/Rab4 expression is unknown. Therefore, we determined how lupus-associated polymorphic rs451401 alleles of the LTR regulate transcription from the HRES-1/Rab4 promoter and thus affect T cell activation. The results showed that cytosine –119 is hypermethylated while cytosine –51 of the promoter and the LTR enhancer are hypomethylated in SLE. Pharmacologic or genetic inactivation of DNA methyltransferase 1 augmented the expression of HRES-1/Rab4. The minimal promoter was selectively recognized by metabolic stress sensor NRF1 when cytosine –119 but not cytosine –51 was methylated, and NRF1 stimulated HRES-1/Rab4 expression in human T cells. In turn, IRF2 and PSIP1 bound to the LTR enhancer and exerted control over HRES-1/Rab4 expression in rs451401 genotype– and methylation-dependent manners. The LTR enhancer conferred markedly greater expression of HRES-1/Rab4 in subjects with rs451401CC over rs451401GG alleles that in turn promoted mechanistic target of rapamycin (mTOR) activation upon T cell receptor stimulation. HRES-1/Rab4 alone robustly activated mTOR in human T cells. These findings identify HRES-1/Rab4 as a methylation- and rs451401 allele–dependent transducer of environmental stress and controller of T cell activation.
Comment on: “The Geographic Diversity of Spinocerebellar Ataxias (SCAs) in the Americas: A Systematic Review”
Al‐Shaikh, Rana Hanna , Hanna Al-Shaikh, Rana, Wszołek, Zbigniew K.

Mayo Clinic

Movement Disorders Clinical Practice | December 5, 2019 | Volume: 7 | Issue: 2 | Pages: 237-238

10.1002/mdc3.12878 | PMID 32071949 Get It

Integrative Omics Approach to Identifying Genes Associated With Atrial Fibrillation
Wang, Biqi , Lunetta, Kathryn L. , Lubitz, Steven A. , Trinquart, Ludovic , Yao, Lixia , Benjamin, Emelia J. , Benjamin, Emelia J , Lubitz, Steven A , Dupuis, Josée , Ellinor, Patrick T. , Lin, Honghuang

Mayo Clinic

Circulation Research | December 5, 2019 | Volume: 126 | Issue: 3 | Pages: 350-360

10.1161/circresaha.119.315179 | PMID 31801406 Get It

Rationale: GWAS (Genome-Wide Association Studies) have identified hundreds of genetic loci associated with atrial fibrillation (AF). However, these loci explain only a small proportion of AF heritability. Objective: To develop an approach to identify additional AF-related genes by integrating multiple omics data. Methods and Results: Three types of omics data were integrated: (1) summary statistics from the AFGen 2017 GWAS; (2) a whole blood EWAS (Epigenome-Wide Association Study) of AF; and (3) a whole blood TWAS (Transcriptome-Wide Association Study) of AF. The variant-level GWAS results were collapsed into gene-level associations using fast set-based association analysis. The CpG-level EWAS results were also collapsed into gene-level associations by an adapted SNP-set Kernel Association Test approach. Both GWAS and EWAS gene-based associations were then meta-analyzed with TWAS using a fixed-effects model weighted by the sample size of each data set. A tissue-specific network was subsequently constructed using the NetWAS (Network-Wide Association Study). The identified genes were then compared with the AFGen 2018 GWAS that contained more than triple the number of AF cases compared with AFGen 2017 GWAS. We observed that the multiomics approach identified many more relevant AF-related genes than using AFGen 2018 GWAS alone (1931 versus 206 genes). Many of these genes are involved in the development and regulation of heart- and muscle-related biological processes. Moreover, the gene set identified by multiomics approach explained much more AF variance than those identified by GWAS alone (10.4% versus 3.5%). Conclusions: We developed a strategy to integrate multiple omics data to identify AF-related genes. Our integrative approach may be useful to improve the power of traditional GWAS, which might be particularly useful for rare traits and diseases with limited sample size.
Spatiotemporal dynamics and heterogeneity of renal lymphatics in mammalian development and cystic kidney disease
Jafree, Daniyal J. , Moulding, Dale , Kolatsi‐Joannou, Maria , Tejedor, Nuria Perretta, Price, Karen , Milmoe, Natalie J., Correra, Rosa Maria, Winyard, Paul J.D. , Harris, Peter C. , Riley, Paul R. , Woolf, Adrian S. , Scambler, Peter , Long, David A. , Riley, Paul R , Woolf, Adrian S , Long, David A , Harris, Peter C , Walsh, Claire , Ruhrberg, Christiana , Walker‐Samuel, Simon

Mayo Clinic

eLife | December 5, 2019 | Volume: 8 | Issue: No issue available | Pages: No page available

10.7554/elife.48183 | PMID 31808745 Get It

Heterogeneity of lymphatic vessels during embryogenesis is critical for organ-specific lymphatic function. Little is known about lymphatics in the developing kidney, despite their established roles in pathology of the mature organ. We performed three-dimensional imaging to characterize lymphatic vessel formation in the mammalian embryonic kidney at single-cell resolution. In mouse, we visually and quantitatively assessed the development of kidney lymphatic vessels, remodeling from a ring-like anastomosis under the nascent renal pelvis; a site of VEGF-C expression, to form a patent vascular plexus. We identified a heterogenous population of lymphatic endothelial cell clusters in mouse and human embryonic kidneys. Exogenous VEGF-C expanded the lymphatic population in explanted mouse embryonic kidneys. Finally, we characterized complex kidney lymphatic abnormalities in a genetic mouse model of polycystic kidney disease. Our study provides novel insights into the development of kidney lymphatic vasculature; a system which likely has fundamental roles in renal development, physiology and disease.
International consensus statements for endoscopic management of distal biliary stricture
Nakai, Yousuke , Rerknimitr, Rungsun , Khor, Christopher , Yasuda, Ichiro , Lau, James Y. , Lakhtakia, Sundeep , Ratanachu‐ek, Thawee , Lee, Dong Ki , Makmun, Dadang , Dy, Frederick, Draganov, Peter V. , Almadi, Majid A. , Ryozawa, Shomei , Wallace, Michael B. , Itoi, Takao , Devereaux, Benedict , Aniwan, Satimai , Makmun, Dadang , Rerknimitr, Rungsun , Yasuda, Ichiro , Lau, James , Lakhtakia, Sundeep , Kitano, Masayuki , Devereaux, Benedict , Wallace, Michael B , Isayama, Hiroyuki , Wang, Hsiu‐Po , Kogure, Hirofumi , Moon, Jong Ho , Seo, Dong Wan , Liao, Wei‐Chih , Irisawa, Atsushi , Katanuma, Akio , Fujisawa, Toshio

Mayo Clinic

Journal of Gastroenterology and Hepatology | December 5, 2019 | Volume: 35 | Issue: 6 | Pages: 967-979

10.1111/jgh.14955 | PMID 31802537 Get It

AbstractDistal biliary strictures (DBS) are common and may be caused by both malignant and benign pathologies. While endoscopic procedures play a major role in their management, a comprehensive review of the subject is still lacking. Our consensus statements were formulated by a group of expert Asian pancreatico‐biliary interventional endoscopists, following a proposal from the Digestive Endoscopy Society of Taiwan, the Thai Association for Gastrointestinal Endoscopy, and the Tokyo Conference of Asian Pancreato‐biliary Interventional Endoscopy. Based on a literature review utilizing Medline, Cochrane library, and Embase databases, a total of 19 consensus statements on DBS were made on diagnosis, endoscopic drainage, benign biliary stricture, malignant biliary stricture, and management of recurrent biliary obstruction and other complications. Our consensus statements provide comprehensive guidance for the endoscopic management of DBS.
Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)
Mehrotra, Shailly , Gray, Elizabeth, Wu, Kehua, Barry, William T., Hudis, Clifford A. , Lyss, Alan P., Toppmeyer, Deborah , Moreno‐Aspitia, Alvaro , Lad, Thomas E. , Velasco, Mario R. , Overmoyer, Beth , Ratain, Mark J. , Sharma, Manish R. , Gray, Elizabeth, Winer, Eric P. , Rugo, Hope S. , Gobburu, Jogarao , Sharma, Manish R.

Mayo Clinic

The Journal of Clinical Pharmacology | December 5, 2019 | Volume: 60 | Issue: 4 | Pages: 444-452

10.1002/jcph.1559 | PMID 31802506 Get It

AbstractChemotherapy‐induced peripheral neuropathy (henceforth, neuropathy) is often dose limiting and is generally managed by empirical dose modifications. We aimed to (1) identify an early time point that is predictive of future neuropathy using a patient‐reported outcome and (2) propose a dose‐adjustment algorithm based on simulated data to manage neuropathy. In previous work, a dose‐neuropathy model was developed using dosing and patient‐reported outcome data from Cancer and Leukemia Group B 40502 (Alliance), a randomized phase III trial of paclitaxel, nanoparticle albumin–bound paclitaxel or ixabepilone as first‐line chemotherapy for locally recurrent or metastatic breast cancer. In the current work, an early time point that is predictive of the future severity of neuropathy was identified based on predictive accuracy of the model. Using the early data and model parameters, simulations were conducted to propose a dose‐adjustment algorithm for the prospective management of neuropathy in individual patients. The end of the first 3 cycles (12 weeks) was identified as the early time point based on a predictive accuracy of 75% for the neuropathy score after 6 cycles. For paclitaxel, nanoparticle albumin–bound paclitaxel, and ixabepilone, simulations with the proposed dose‐adjustment algorithm resulted in 61%, 48%, and 35% fewer patients, respectively, with neuropathy score ≥8 after 6 cycles compared to no dose adjustment. We conclude that early patient‐reported outcome data on neuropathy can be used to guide dose adjustments in individual patients that reduce the severity of future neuropathy. Prospective validation of this approach should be undertaken in future studies.